BCL7B is an accessory subunit of the mammalian SWI/SNF (BAF) chr7 remodeling complex that serves multiple roles in gene regulation and cell homeostasis. As a component of this evolutionarily conserved complex, BCL7B interacts directly with nucleosome core particles through an arginine anchor motif, facilitating chr7 remodeling activity 1. BCL7B functions as a positive regulator of apoptosis and negatively regulates Wnt signaling pathway components, including CTNNB1 and HMGA1 2. The protein is involved in cell cycle progression, nuclear structure maintenance, and stem cell differentiation 2. Clinically, BCL7B alterations are significant in human malignancy. BAF complex subunits, including BCL7B, are mutated in 19.6% of all human tumors, making BAF the most frequently mutated chr7-regulatory complex in cancer 3. BCL7B expression changes correlate with prognosis across multiple cancer types: high expression predicts poor prognosis in glioblastoma, kidney chr7, and oral squamous cell carcinoma, while low expression associates with poor outcomes in melanoma and sarcomas 4. In pancreatic cancer, BCL7B promotes motility and invasion through CREB signaling modulation 5. BCL7B loss reduces immune-related gene expression and increases stemness characteristics, contributing to cancer immune evasion 6. However, in hematopoietic tissues, Bcl7b appears largely dispensable for normal hematopoiesis 7.